Gov. Tony Evers and the Wisconsin Economic Development Corp. (WEDC) on Tuesday joined Catalent leaders and officials to celebrate the company’s recent announcement of an estimated $45 million investment to expand its facilities and purchase new equipment for its production facility in Madison, which has created approximately 200 new, highly skilled jobs.
Evers announced that his administration, through WEDC, is supporting Catalent’s expansion by authorizing up to $2 million in performance-based business development tax credits. The actual amount of tax credits received is contingent upon the number of jobs created and the amount of capital investment during that period.
Catalent works with its pharmaceutical, biotech and consumer health partners to optimize product development, launch and full life-cycle supply for patients around the world. The company supplies billions of doses of life-enhancing and life-saving treatments for patients annually.
Catalent’s Madison facility provides development, manufacturing and analytical services for new biological therapies. The Madison facility also houses the company’s proprietary GPEx Lightning cell line technology, which is used to create high-yielding mammalian cell lines that are genetically modified to create large quantities of a desired protein. The facility features state-of-the-art development and manufacturing labs for pre-clinical, clinical and commercial production of biologics from 50- to 4,000-liter scale.
